Profit cycle designed to benefit hospitals and patients
FINBB is publicly owned and is structured to deliver profit back to hospital districts to enable reinvestment in patient services and treatments.
E.g. If research is carried out in partnership with a pharmaceutical company to define subjects for a clinical trial, compensation earned from the use of public biobank data, will be invested back into regional hospitals and/or universities. In the long run this will benefit Finnish society.
The understanding that shared health information can lead to shared health benefit is becoming a national phenomenon. Patients admitted to all connected university hospitals are encouraged to give biobank consent. Of patients giving a biobank consent, 88% want to promote medical research with their consent. The second most important reason for consenting was the benefit to future generations and the third most important reason was potentially obtaining new information on one’s health (according to the results of a study conducted by the BBMRI.fi biobank network in Finland in 2017).